More than just fun and games: ACTIVE Workspace volume video game quantifies upper extremity function in individuals with neuromuscular disease (S31.004)
Objective: Investigate the validity and clinical meaningfulness of measuring upper extremity workspace volume and trunk control with a custom designed video game called ACTIVE. Background: Accurate assessment and monitoring of upper extremity function is critical, clinically and in research. ACTIVE, a 70 second video game, quantifies reaching workspace volume and trunk control on a continuous scale across a wide range of patient abilities. The Microsoft Kinect tracks the seated participant's movement as he/she reaches over head, forward and laterally to either squish spiders or dig for jewels. ACTIVE quantifies the volume of space that the player reached in cubic meters and how far he/she leaned in centimeters. Scaled scores based on the player's wingspan can be compared to other patients or to accommodate for growth. Design/Methods: Over 300 individuals with a variety of neuromuscular diseases (largest groups are Duchenne muscular dystrophy (DMD) and spinal muscular atrophy (SMA) completed two ACTIVE trials, and a battery of traditional outcome measures appropriate for their age and diagnosis. These included the PROMIS parent report of upper extremity function, North Star Ambulatory Assessment (NSAA) Six Minute Walk Test (6MWT) 100 meter timed test (100m) Performance of Upper Limb (PUL) Hammersmith Functional Motor Scale Expanded (HFMSE) Revised Upper Limb Module (RULM) Results: ACTIVE differentiated between patients of varying severity in DMD, SMA (both p P P Conclusions: ACTIVE can accurately quantify arm abilities and track meaningful functional changes in patients with neuromuscular disease. Future research will assess the validity of ACTIVE in other neurologic conditions such as stroke or cerebral palsy. Study Supported by: The Office of Technology Commercialization at Nationwide Children's Hospital Disclosure: Dr. Alfano has nothing to disclose. Dr. Miller has nothing to disclose. Dr. Iammarino has nothing to disclose. Dr. Dugan has nothing to disclose. Dr. Moore Clingenpeel has nothing to disclose. Dr. Kissel has received research support from Novartis, Biomarin, Cytokinetics, CSL Behring, Avexis, Ionis Pharmaceuticals, Quintiles, Axelacare. Dr. Al Zaidy has nothing to disclose. Dr. Flanigan has nothing to disclose. Dr. Mendell has received research support from Investigator in clinical studies funded by AveXis, Inc. Dr. Lowes has nothing to disclose.